<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185223</url>
  </required_header>
  <id_info>
    <org_study_id>ML 22371</org_study_id>
    <nct_id>NCT01185223</nct_id>
  </id_info>
  <brief_title>Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation</brief_title>
  <acronym>CONVINCE</acronym>
  <official_title>Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierrel Research Europe GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierrel Research Europe GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of oral valganciclovir
      versus intravenous ganciclovir in patients following allogenic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2010</start_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and Safety of oral valganciclovir versus intravenous ganciclovir</measure>
    <time_frame>max. 2 years (recruitement time)</time_frame>
    <description>Main variable for efficacy in the primary endpoint will be evaluated by assessment of the event-free survival within 180 days after stem cell transplantation.
Main variable for safety in the primary endpoint will be evaluated by the porpotion of patients with severe neutropenia until 7 days after discontinuation of antiviral therapy with the study drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined secondary endpoint of efficacy and safety</measure>
    <time_frame>max. 2 years (recruitement time)</time_frame>
    <description>The secondary variables of efficacy will be:
The proportion of patients with persistently positive blood specimens for CMV after completion of antiviral therapy with the Study Drug,
The proportion of patients who require retreatment after discontinuation of antiviral therapy with the Study Drug until day 180,
The proportion of patients with CMV disease within 180 days after SCT,
The number of days patients were alive and not hospitalized between randomization and day 180 post SCT,
The proportion of patients who died from any cause within 180 days after SCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Valganciclovir</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ganciclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL</description>
    <arm_group_label>Valganciclovir</arm_group_label>
    <other_name>Ro 107-9070</other_name>
    <other_name>Valcyte</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
    <description>2x5mg/kg/d intravenous ganciclovir</description>
    <arm_group_label>Ganciclovir</arm_group_label>
    <other_name>Cymeven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient following allogeneic SCT

          -  Patient with a first episode of positive CMV-PCR (DNAemia) or pp65 antigenemia assay
             (antigenemia) up to 100 days after SCT

          -  Absolute neutrophil count (ANC) ≥1000 cells/µL on 2 consecutive follow-ups within 10
             days before randomization

          -  Patient has a creatinine clearance of ≥25 mL/min (calculated by the Cockcroft-Gault
             formula, see Part I Section 6.1.2) with evidence of improving renal function,

          -  None or gastrointestinal graft-versus-host disease (GVHD) up to grade 2

        Exclusion Criteria:

          -  Patient has a suspected or diagnosed CMV disease

          -  Patient has received syngeneic SCT

          -  Patient who received an investigational medicinal product (IMP) within the last 30
             days prior to screening or who is simultaneously participating in another clinical
             study with an IMP

          -  Patient with a body weight &lt;50 kg or &gt;95 kg,

          -  Patient has received anti-CMV therapy within the past 30 days prior to screening (the
             use of acyclovir, valacyclovir, or famciclovir is permitted)

          -  Patient who has participated in this study before,

          -  Patient who shows a neutropenia, thrombocytopenia, or anemia within 10 days before or
             at the time point of randomization as following:

               -  The ANC is &lt;1000 cells/μL on 2 consecutive follow-ups, or

               -  A platelet count of ≥25000/μL can not be achieved/maintained with platelet
                  transfusions

               -  A hemoglobin level of ≥8g/dL can not be achieved/maintained by red blood cell
                  transfusions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hermann Einsele, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pierrel Site 50</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 12</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 13</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 9</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 3</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 7</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 5</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 4</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 8</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 10</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 1</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 32</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site33</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 30</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 34</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 31</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pierrel Site 35</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <last_update_submitted>December 7, 2012</last_update_submitted>
  <last_update_submitted_qc>December 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>Pierrel Research Europe GmbH</name_title>
    <organization>Pierrel Research Europe GmbH</organization>
  </responsible_party>
  <keyword>Valganciclovir</keyword>
  <keyword>Ganciclovir</keyword>
  <keyword>Antiviral Drug</keyword>
  <keyword>CMV disease</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

